(OCSL) Oaktree Specialty Lending - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US67401P4054
Stock: Debt Financing, Equity Investments, Middle Market, Acquisitions
Total Rating 25
Risk 39
Buy Signal -0.68
| Risk 5d forecast | |
|---|---|
| Volatility | 22.1% |
| Relative Tail Risk | 5.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.85 |
| Alpha | -30.08 |
| Character TTM | |
|---|---|
| Beta | 0.584 |
| Beta Downside | 0.869 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.16% |
| CAGR/Max DD | -0.11 |
EPS (Earnings per Share)
Revenue
Description: OCSL Oaktree Specialty Lending March 04, 2026
Oaktree Specialty Lending Corporation (OCSL) operates as a business development company (BDC), a type of investment vehicle that provides debt and equity financing to small and mid-sized companies.
OCSL focuses on middle-market companies, offering various debt instruments including first and second lien debt, unsecured loans, and mezzanine financing. This sector typically involves companies with enterprise values between $20 million and $150 million and EBITDA between $3 million and $50 million.
The firm targets a broad range of industries, such as education, healthcare, manufacturing, and technology. Investment amounts typically range from $5 million to $75 million per company, with a focus on North American businesses.
To deepen your understanding of OCSLs investment strategies and performance, consider exploring detailed analytics on ValueRay.
Headlines to watch out for
- Interest rate fluctuations impact loan profitability
- Credit quality of middle-market borrowers affects defaults
- Competition for debt investments compresses yields
- Regulatory changes for BDCs alter operating costs
- Economic downturns increase portfolio company risk
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 32.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.69 > 1.0 |
| NWC/Revenue: 16.44% < 20% (prev 112.9%; Δ -96.44% < -1%) |
| CFO/TA 0.03 > 3% & CFO 79.4m > Net Income 32.3m |
| Net Debt (1.53b) to EBITDA (85.9m): 17.81 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.1m) vs 12m ago 7.10% < -2% |
| Gross Margin: 62.22% > 18% (prev 0.28%; Δ 6.19k% > 0.5%) |
| Asset Turnover: 6.99% > 50% (prev 5.70%; Δ 1.29% > 0%) |
| Interest Coverage Ratio: 0.77 > 6 (EBITDA TTM 85.9m / Interest Expense TTM 111.9m) |
Altman Z'' -1.28
| A: 0.01 (Total Current Assets 80.8m - Total Current Liabilities 45.3m) / Total Assets 3.10b |
| B: -0.30 (Retained Earnings -914.8m / Total Assets 3.10b) |
| C: 0.03 (EBIT TTM 85.9m / Avg Total Assets 3.09b) |
| D: -0.55 (Book Value of Equity -913.9m / Total Liabilities 1.66b) |
| Altman-Z'' Score: -1.28 = CCC |
Beneish M
| DSRI: 0.19 (Receivables 23.9m/103.2m, Revenue 216.1m/175.9m) |
| GMI: 0.45 (GM 62.22% / 27.79%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.23 (Revenue 216.1m / 175.9m) |
| TATA: -0.02 (NI 32.3m - CFO 79.4m) / TA 3.10b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of OCSL shares?
As of March 24, 2026, the stock is trading at USD 11.34 with a total of 719,959 shares traded.
Over the past week, the price has changed by +5.19%, over one month by +3.74%, over three months by -6.93% and over the past year by -17.73%.
Over the past week, the price has changed by +5.19%, over one month by +3.74%, over three months by -6.93% and over the past year by -17.73%.
Is OCSL a buy, sell or hold?
Oaktree Specialty Lending has received a consensus analysts rating of 3.33.
Therefor, it is recommend to hold OCSL.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OCSL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.8 | 12.6% |
| Analysts Target Price | 12.8 | 12.6% |
OCSL Fundamental Data Overview March 21, 2026
P/E Trailing = 31.25
P/E Forward = 7.7042
P/S = 3.2464
P/B = 0.69
P/EG = 0.9343
Revenue TTM = 216.1m USD
EBIT TTM = 85.9m USD
EBITDA TTM = 85.9m USD
Long Term Debt = 1.51b USD (estimated: total debt 1.61b - short term 98.4m)
Short Term Debt = 98.4m USD (from shortTermDebt, last quarter)
Debt = 1.61b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 2.52b USD (991.0m + Debt 1.61b - CCE 80.8m)
Interest Coverage Ratio = 0.77 (Ebit TTM 85.9m / Interest Expense TTM 111.9m)
EV/FCF = 31.75x (Enterprise Value 2.52b / FCF TTM 79.4m)
FCF Yield = 3.15% (FCF TTM 79.4m / Enterprise Value 2.52b)
FCF Margin = 36.72% (FCF TTM 79.4m / Revenue TTM 216.1m)
Net Margin = 14.94% (Net Income TTM 32.3m / Revenue TTM 216.1m)
Gross Margin = 62.22% ((Revenue TTM 216.1m - Cost of Revenue TTM 81.7m) / Revenue TTM)
Gross Margin QoQ = 87.83% (prev 84.43%)
Tobins Q-Ratio = 0.81 (Enterprise Value 2.52b / Total Assets 3.10b)
Interest Expense / Debt = 1.66% (Interest Expense 26.7m / Debt 1.61b)
Taxrate = 0.64% (36.0k / 5.64m)
NOPAT = 85.3m (EBIT 85.9m * (1 - 0.64%))
Current Ratio = 1.78 (Total Current Assets 80.8m / Total Current Liabilities 45.3m)
Debt / Equity = 1.12 (Debt 1.61b / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = 17.81 (Net Debt 1.53b / EBITDA 85.9m)
Debt / FCF = 19.27 (Net Debt 1.53b / FCF TTM 79.4m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.04% (Net Income 32.3m / Total Assets 3.10b)
RoE = 2.21% (Net Income TTM 32.3m / Total Stockholder Equity 1.46b)
RoCE = 2.89% (EBIT 85.9m / Capital Employed (Equity 1.46b + L.T.Debt 1.51b))
RoIC = 2.88% (NOPAT 85.3m / Invested Capital 2.96b)
WACC = 4.08% (E(991.0m)/V(2.60b) * Re(8.04%) + D(1.61b)/V(2.60b) * Rd(1.66%) * (1-Tc(0.01)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.38%
[DCF] Terminal Value 82.52% ; FCFF base≈112.4m ; Y1≈82.2m ; Y5≈46.6m
[DCF] Fair Price = N/A (negative equity: EV 1.45b - Net Debt 1.53b = -80.5m; debt exceeds intrinsic value)
EPS Correlation: -68.74 | EPS CAGR: -7.08% | SUE: 1.02 | # QB: 1
Revenue Correlation: 17.11 | Revenue CAGR: 33.84% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=-0.004 | Chg30d=+0.002 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-09-30): EPS=1.51 | Chg7d=-0.006 | Chg30d=+0.005 | Revisions Net=-1 | Growth EPS=-14.3% | Growth Revenue=-5.8%
EPS next Year (2027-09-30): EPS=1.47 | Chg7d=-0.015 | Chg30d=+0.004 | Revisions Net=-1 | Growth EPS=-2.5% | Growth Revenue=-0.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.8% (Discount Rate 8.0% - Earnings Yield 3.2%)
[Growth] Growth Spread = -5.7% (Analyst -0.9% - Implied 4.8%)
P/E Forward = 7.7042
P/S = 3.2464
P/B = 0.69
P/EG = 0.9343
Revenue TTM = 216.1m USD
EBIT TTM = 85.9m USD
EBITDA TTM = 85.9m USD
Long Term Debt = 1.51b USD (estimated: total debt 1.61b - short term 98.4m)
Short Term Debt = 98.4m USD (from shortTermDebt, last quarter)
Debt = 1.61b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 2.52b USD (991.0m + Debt 1.61b - CCE 80.8m)
Interest Coverage Ratio = 0.77 (Ebit TTM 85.9m / Interest Expense TTM 111.9m)
EV/FCF = 31.75x (Enterprise Value 2.52b / FCF TTM 79.4m)
FCF Yield = 3.15% (FCF TTM 79.4m / Enterprise Value 2.52b)
FCF Margin = 36.72% (FCF TTM 79.4m / Revenue TTM 216.1m)
Net Margin = 14.94% (Net Income TTM 32.3m / Revenue TTM 216.1m)
Gross Margin = 62.22% ((Revenue TTM 216.1m - Cost of Revenue TTM 81.7m) / Revenue TTM)
Gross Margin QoQ = 87.83% (prev 84.43%)
Tobins Q-Ratio = 0.81 (Enterprise Value 2.52b / Total Assets 3.10b)
Interest Expense / Debt = 1.66% (Interest Expense 26.7m / Debt 1.61b)
Taxrate = 0.64% (36.0k / 5.64m)
NOPAT = 85.3m (EBIT 85.9m * (1 - 0.64%))
Current Ratio = 1.78 (Total Current Assets 80.8m / Total Current Liabilities 45.3m)
Debt / Equity = 1.12 (Debt 1.61b / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = 17.81 (Net Debt 1.53b / EBITDA 85.9m)
Debt / FCF = 19.27 (Net Debt 1.53b / FCF TTM 79.4m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.04% (Net Income 32.3m / Total Assets 3.10b)
RoE = 2.21% (Net Income TTM 32.3m / Total Stockholder Equity 1.46b)
RoCE = 2.89% (EBIT 85.9m / Capital Employed (Equity 1.46b + L.T.Debt 1.51b))
RoIC = 2.88% (NOPAT 85.3m / Invested Capital 2.96b)
WACC = 4.08% (E(991.0m)/V(2.60b) * Re(8.04%) + D(1.61b)/V(2.60b) * Rd(1.66%) * (1-Tc(0.01)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.38%
[DCF] Terminal Value 82.52% ; FCFF base≈112.4m ; Y1≈82.2m ; Y5≈46.6m
[DCF] Fair Price = N/A (negative equity: EV 1.45b - Net Debt 1.53b = -80.5m; debt exceeds intrinsic value)
EPS Correlation: -68.74 | EPS CAGR: -7.08% | SUE: 1.02 | # QB: 1
Revenue Correlation: 17.11 | Revenue CAGR: 33.84% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=-0.004 | Chg30d=+0.002 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-09-30): EPS=1.51 | Chg7d=-0.006 | Chg30d=+0.005 | Revisions Net=-1 | Growth EPS=-14.3% | Growth Revenue=-5.8%
EPS next Year (2027-09-30): EPS=1.47 | Chg7d=-0.015 | Chg30d=+0.004 | Revisions Net=-1 | Growth EPS=-2.5% | Growth Revenue=-0.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.8% (Discount Rate 8.0% - Earnings Yield 3.2%)
[Growth] Growth Spread = -5.7% (Analyst -0.9% - Implied 4.8%)